Phathom spikes as Cantor Fitzgerald bullish on IP claims
Phathom Pharmaceuticals (PHAT) stock rises as Cantor Fitzgerald issues an Overweight rating, rejecting its IP-rights related ...
Cantor Fitzgerald maintains $118 target on Ultragenyx stock
Cantor Fitzgerald reaffirmed its Overweight rating and $118.00 price target for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company specializing in rare diseases. Currently ...
Phathom Pharmaceuticals initiated at Cantor Fitzgerald on ‘significant’ upside
Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals (PHAT) with an Overweight rating and $23 price target The firm cited ...
Hosted on MSN21h
Cantor Fitzgerald Initiates Coverage of GH Research (GHRS) with Overweight Recommendation
Fintel reports that on February 13, 2025, Cantor Fitzgerald initiated coverage of GH Research (NasdaqGM:GHRS) with a ...
Seabridge Gold Announces US$100 Million in Financings Includes US$20 million from Strategic Investor
Seabridge Gold Inc. (TSX: SEA) (NYSE: SA) ("Seabridge" or the "Company") announced today it has entered into an agreement with RBC Capital Markets and Cantor Fitzgerald Canada Corporation (together ...
Cantor Fitzgerald Keeps Their Buy Rating on Iris Energy (IREN)
In a report released yesterday, Brett Knoblauch from Cantor Fitzgerald reiterated a Buy rating on Iris Energy (IREN – Research Report), with a ...
Deals Keep Moving, but M&A Value Fell in January
M&A markets don't like volatility and unpredictability, and what we've seen in the past few weeks is the opposite of that,” ...